KF
ESPR

Krilogy Financial’s Esperion Therapeutics ESPR Stock Holding History

Krilogy Financial’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.3K Buy
+11,472
New +$32.1K ﹤0.01% 1046
2017
Q4 		– Sell
-200
Closed -$10K – 786
2017
Q3 		$10K Hold
200
– – ﹤0.01% 576
2017
Q2 		$9K Hold
200
– – ﹤0.01% 542
2017
Q1 		$3K Hold
200
– – ﹤0.01% 618
2016
Q4 		$3K Hold
200
– – ﹤0.01% 618
2016
Q3 		$3K Hold
200
– – ﹤0.01% 634
2016
Q2 		$2K Hold
200
– – ﹤0.01% 678
2016
Q1 		$3K Hold
200
– – ﹤0.01% 576
2015
Q4 		$4K Hold
200
– – ﹤0.01% 330
2015
Q3 		$5K Buy
+200
New +$12.6K ﹤0.01% 463

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Krilogy Financial's ESPR Position: Q2 2026 in Review

Krilogy Financial opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 11,472 shares worth $36.3K. The stake represents ﹤0.01% of the portfolio and ranks #1046 among its holdings. This is a return to the name: Krilogy Financial previously reported a position in ESPR as recently as Q3 2017.

Krilogy Financial first reported a position in ESPR in Q3 2015 and has held it in 10 quarters since. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Krilogy Financial held 11,472 shares of Esperion Therapeutics worth $36.3K as of Q2 2026.
  • Esperion Therapeutics was a new Krilogy Financial position in Q2 2026.
  • Esperion Therapeutics made up ﹤0.01% of Krilogy Financial's portfolio in Q2 2026, its #1046 holding.
  • Krilogy Financial first reported a position in Esperion Therapeutics in Q3 2015 and has held it in 10 quarters since.
  • 192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Krilogy Financial's 13F filing for Q2 2026, filed 27 Jul 2026.